NCT00628433View on ClinicalTrials.gov

Safety and Pharmacokinetics Study of HE3286 in Patients With Active, Mild-to-Moderate Ulcerative Colitis

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

February 29, 2008

Primary Completion Date

May 31, 2009

Study Completion Date

May 31, 2009

Conditions
Ulcerative Colitis
Interventions
DRUG

Placebo

Placebo

DRUG

HE3286

daily for 28 days

Trial Locations (10)

30342

Atlanta

32789

Winter Park

40536

Louisville

79905

El Paso

80205

Denver

80215

Denver

85712

Tucson

92037

La Jolla

92801

Anaheim

93726

Fresno

Sponsors
All Listed Sponsors
lead

Harbor Therapeutics

INDUSTRY